An observational study in Pneumonia and Bacterial, sponsored by Bule Hora University. Completed at 1 site in Ethiopia. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2025-02-19.
Sponsored by Bule Hora University · Observational
A prospective observational study design was conducted on children admitted to the pediatric wards of Jimma Medical Center. The study was conducted from February 03, 2022, to June 03, 2022, and patients aged \< 18 years and diagnosed with pneumonia were included. A chart review supplemented by a self-administered questionnaire was used to collect data. Descriptive statistics and binary logistic regressions were performed for data analyses.
2.2 Study Design A hospital-based prospective observational study was conducted in children with pneumonia admitted to the pediatric ward of Jimma Medical Center.
2.3 Participant Eligibility and Inclusion All pediatric patients admitted to the pediatric ward of the Jimma Medical Center with a diagnosis of pneumonia during the study period were screened for eligibility criteria. Patients aged less than or equal to 18 years admitted to the pediatric wards of Jimma Medical Center with a suspected or proven pneumonia diagnosis by physician decision on duty during the study period and Patients whose parents gave assent were included in the study. Patients who died before they started antimicrobial, transferred to other facilities and patient lost follow-up were excluded.
2.4 Sample Size and Sampling Technique No sampling technique was applied; instead, all pediatric patients diagnosed with pneumonia that fulfilled illegibility criteria during the study period were recruited in the study. Accordingly, 146 patients were followed and completed data collected.
2.5 Data Collection Instrument and Quality Assurance The data collections instrument (data abstraction format and self-administered questionnaire) was developed by reviewing the literature on antimicrobial use, antimicrobial resistance, and antimicrobial stewardship program guidelines. Training was given for data collectors on the data collection procedure and research objectives. The principal investigator was regularly checking the consistency and completeness of the data and random checks were also being performed.
2.6 Data Processing and Analysis Data was compiled, cleared, coded, and verified for completeness and accuracy before being included in Epi Data Manager version 4.6.2. Double-entry verification was performed and the data was analyzed using statistical software, SPSS version 25.0. Descriptive statistics (mean, frequency, and cross tabulation) were used to describe practice of antimicrobial use. The bivariate logistic regression was performed for clinical outcome and variables with p-values less than 0.25 with outcomes (poor outcome or good outcome) were taken into account for further analysis. Then, the independent predictors were identified by multivariate logistic regression analysis. All statistical tests were detailed; a P value of less than or equal to 0.05 was considered statistically significant.
2,072 studies on the registry are indexed under Pneumonia; 286 are open to participants now.
This study's enrollment of 161 is below the median of 200 across 699 observational studies indexed under Pneumonia.
Browse Pneumonia studies →Bule Hora University is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
All pediatric patients admitted to the pediatric ward of the Jimma Medical Center with a diagnosis of pneumonia during the study period were screened for eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention made
Antibiotics use pattern
Current practice of antimicrobial agents
Time frame: February 03,2022 to June 03,2022
Clinical outcome
Clinical treatment outcome(As poor vs good)
Time frame: February 03,2022 to June 03,2022
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2022 to primary completion in Jun 2022, 4 months.
Of 272 non-industry observational studies under Pneumonia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 56. This study's 4 months is below that.
Counting every sponsor, half of 281 studies reached it within 25 months; a quarter within 14 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bule Hora University